3 results
Approved WMORecruiting
To compare progression-free survival (PFS) of LOXO-305 as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL).
Approved WMOCompleted
The purpose of this study is to evaluate how safe telisotuzumab vedotin is and how telisotuzumab vedotin is tolerated as monotherapy and in combination with osimertinib.
Approved WMORecruiting
Primary objectivesTime needed for proper closure of the trocar wounds with the automated deviceSecondary objectivesDemonstrate user-friendliness of the Mediclose System